Therapeutic Applications of Pretargeting

Targeted therapies, such as radioimmunotherapy (RIT), present a promising treatment option for the eradication of tumor lesions. RIT has shown promising results especially for hematologic malignancies, but the therapeutic efficacy is limited by unfavorable tumor-to-background ratios resulting in high radiotoxicity. Pretargeting strategies can play an important role in addressing the high toxicity profile of RIT. Key to pretargeting is the concept of decoupling the targeting vehicle from the cytotoxic agent and administrating them separately. Studies have shown that this approach has the ability to enhance the therapeutic index as it can reduce side effects caused by off-target irradiation and thereby increase curative effects due to higher tolerated doses. Pretargeted RIT (PRIT) has been explored for imaging and treatment of different cancer types over the years. This review will give an overview of the various targeted therapies in which pretargeting has been applied, discussing PRIT with alpha- and beta-emitters and as part of combination therapy, plus its use in drug delivery systems.

[1]  S. Majewski,et al.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers , 2019, Journal of Nuclear Cardiology.

[2]  T. Buckle,et al.  In vivo stability of supramolecular host–guest complexes monitored by dual‐isotope multiplexing in a pre‐targeting model of experimental liver radioembolization , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Guozheng Liu A Revisit to the Pretargeting Concept—A Target Conversion , 2018, Front. Pharmacol..

[4]  Jason S. Lewis,et al.  Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma , 2018, Clinical Cancer Research.

[5]  S. Larson,et al.  Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma , 2018, Theranostics.

[6]  A. Kjaer,et al.  Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. , 2018, Biomaterials.

[7]  Wei Wei,et al.  Amplifying Nanoparticle Targeting Performance to Tumor via Diels–Alder Cycloaddition , 2018 .

[8]  M. Bartholomä Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[9]  A. Karlström,et al.  Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle , 2018, The Journal of Nuclear Medicine.

[10]  J. Kopeček,et al.  Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. , 2018, ACS nano.

[11]  W. Verboom,et al.  A Supramolecular Approach for Liver Radioembolization , 2018, Theranostics.

[12]  Jason S. Lewis,et al.  Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. , 2018, Molecular pharmaceutics.

[13]  K. Wittrup,et al.  CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. , 2018, Blood.

[14]  C. Ahn,et al.  Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo. , 2017, Biomaterials.

[15]  T. Reiner,et al.  Specific Binding of Liposomal Nanoparticles through Inverse Electron‐Demand Diels–Alder Click Chemistry , 2017, ChemistryOpen.

[16]  P. Zanzonico,et al.  Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer , 2017, The Journal of Nuclear Medicine.

[17]  S. Lai,et al.  Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[18]  W. Cai,et al.  α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts , 2017, The Journal of Nuclear Medicine.

[19]  P. Albertsson,et al.  BIOTINYLATED AND CHELATED POLY-L-LYSINE AS EFFECTOR FOR PRETARGETING IN CANCER THERAPY AND IMAGING , 2016 .

[20]  G. Gasser,et al.  New insights into the pretargeting approach to image and treat tumours. , 2016, Chemical Society reviews.

[21]  K. Wittrup,et al.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. , 2016, Cancer research.

[22]  L. Tang,et al.  In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates , 2016, Theranostics.

[23]  S. Prabha,et al.  Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors. , 2016, Biomaterials.

[24]  S. Larson,et al.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Jason S. Lewis,et al.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses , 2016, The Journal of Nuclear Medicine.

[26]  O. Couturier,et al.  Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients , 2015, Front. Med..

[27]  SpagnoliLuigi Giusto,et al.  Radionuclide Therapy of Unresectable Tumors with AvidinOX and 90Y-biotinDOTA: Tongue Cancer Paradigm , 2015 .

[28]  P. Hudson,et al.  Diabody Pretargeting with Click Chemistry In Vivo , 2015, The Journal of Nuclear Medicine.

[29]  C. Albertoni,et al.  Radionuclide Therapy of Unresectable Tumors with AvidinOX and 90Y-biotinDOTA: Tongue Cancer Paradigm , 2015, Cancer biotherapy & radiopharmaceuticals.

[30]  R. Zhang,et al.  A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab , 2015, Theranostics.

[31]  B. Miller,et al.  Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models , 2015, PloS one.

[32]  W. Oyen,et al.  Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy , 2015, EJNMMI Physics.

[33]  W. Oyen,et al.  Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. , 2014, Cancer biotherapy & radiopharmaceuticals.

[34]  D. Artemov,et al.  Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models , 2014, Scientific Reports.

[35]  S. Larson,et al.  Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex , 2014, Molecular Cancer Therapeutics.

[36]  J. Barbet,et al.  Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. , 2014, Nuclear medicine and biology.

[37]  B. Cornelissen,et al.  Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. , 2014, American journal of nuclear medicine and molecular imaging.

[38]  W. Oyen,et al.  Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  S. Majewski,et al.  Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  B. Wood,et al.  A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. , 2014, Cancer research.

[41]  R. Laforest,et al.  Diels–Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody , 2013, The Journal of Nuclear Medicine.

[42]  W. Oyen,et al.  Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results , 2013, British Journal of Cancer.

[43]  A. Hagenbeek,et al.  90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. Oyen,et al.  Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  P. Albertsson,et al.  Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. , 2013, Cancer biotherapy & radiopharmaceuticals.

[46]  J. Andersen,et al.  A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. , 2013, Protein engineering, design & selection : PEDS.

[47]  M. Kaminski,et al.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Kwangmeyung Kim,et al.  Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. , 2012, Angewandte Chemie.

[49]  F. Borson‐Chazot,et al.  Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement , 2012, The Journal of Nuclear Medicine.

[50]  T. Wirth,et al.  Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma , 2012, PloS one.

[51]  S. Severi,et al.  Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival , 2012 .

[52]  H. Lundqvist,et al.  Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles , 2012, The Journal of Nuclear Medicine.

[53]  Yuzhen Wang,et al.  90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. , 2011, Bioconjugate chemistry.

[54]  L. Jacobsson,et al.  In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy. , 2011, Cancer biotherapy & radiopharmaceuticals.

[55]  S. Jurisson,et al.  Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. , 2011, Bioconjugate chemistry.

[56]  P. Stayton,et al.  Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma , 2011, Clinical Cancer Research.

[57]  D. Goldenberg,et al.  Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  F. Appelbaum,et al.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. , 2011, Blood.

[59]  J. Pagel,et al.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. , 2010, Blood.

[60]  W. Oyen,et al.  Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colonic Tumors in Mice , 2010, The Journal of Nuclear Medicine.

[61]  S. Baker,et al.  A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49 , 2010, Cancer biology & therapy.

[62]  J. Schellens,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[63]  P. Musiani,et al.  AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. , 2010, Cancer biotherapy & radiopharmaceuticals.

[64]  R. Rossin,et al.  SYNFORM ISSUE 2010/9 , 2010, Angewandte Chemie.

[65]  W. Mcbride,et al.  Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10–90Y-IMP-288 Alone and Combined with Gemcitabine , 2009, Journal of Nuclear Medicine.

[66]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[67]  J. Pagel,et al.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. , 2009, Blood.

[68]  J. Pagel,et al.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. , 2009, Blood.

[69]  M. Trivett,et al.  The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum , 2009, Journal of immunotherapy.

[70]  W. Mcbride,et al.  Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma , 2009, Journal of Nuclear Medicine.

[71]  F. Appelbaum,et al.  Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. , 2008, Cancer research.

[72]  A. Hagenbeek,et al.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  W. Mcbride,et al.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. , 2008, Cancer research.

[74]  B. Wood,et al.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. , 2008, Blood.

[75]  W. Lu,et al.  Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[76]  W. Quax,et al.  RGD-avidin–biotin pretargeting to αvβ3 integrin enhances the proapoptotic activity of TNFα related apoptosis inducing ligand (TRAIL) , 2007, Apoptosis.

[77]  Riccardo Mei,et al.  Pretargeted antibody‐guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma , 2007, European journal of haematology.

[78]  A. Luini,et al.  IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. , 2007, Breast.

[79]  Xinrong Liu,et al.  Successful Radiotherapy of Tumor in Pretargeted Mice by 188Re-Radiolabeled Phosphorodiamidate Morpholino Oligomer, a Synthetic DNA Analogue , 2006, Clinical Cancer Research.

[80]  J. Pagel,et al.  Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. , 2006, Blood.

[81]  V. Rohmer,et al.  Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Pagel,et al.  A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. , 2006, Cancer research.

[83]  Jacques Barbet,et al.  Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  M. Carpenter,et al.  Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein , 2005, Clinical Cancer Research.

[85]  W. Mcbride,et al.  Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft , 2005, Clinical Cancer Research.

[86]  P. Beaumier,et al.  Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. , 2005, Nuclear medicine and biology.

[87]  S. Shen,et al.  Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. , 2005, Cancer biotherapy & radiopharmaceuticals.

[88]  I. Pastan,et al.  Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  W. Mcbride,et al.  Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody , 2005, Leukemia.

[90]  J. Chatal,et al.  Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  S. Shen,et al.  Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  G. Maira,et al.  Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[93]  J. Vose,et al.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.

[94]  F. Malavasi,et al.  Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin? , 2004, Gynecologic oncology.

[95]  William C Eckelman,et al.  Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin , 2004, Clinical Cancer Research.

[96]  S. Jurisson,et al.  Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. , 2004, Nuclear medicine and biology.

[97]  K. Auditore-Hargreaves,et al.  Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  W. Mcbride,et al.  Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  M. Welch,et al.  In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[100]  Damon L. Meyer,et al.  Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. , 2003, Blood.

[101]  Damon L. Meyer,et al.  Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[102]  T. Waldmann,et al.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[103]  T. Waldmann,et al.  Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin. , 2002, Cancer research.

[104]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[105]  M. Rusckowski,et al.  Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[106]  F. Kraeber-Bodéré,et al.  Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. , 2002, Molecular cancer therapeutics.

[107]  P. Caliceti,et al.  Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study , 2002, British Journal of Cancer.

[108]  P. Weiden Pretargeted Radioimmunotherapy (PRIT™) Using an Antibody-Streptavidin Fusion Protein in Non-Hodgkin's Lymphoma , 2002, Leukemia & lymphoma.

[109]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[110]  P. Weiden,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). , 2001, Critical reviews in oncology/hematology.

[111]  P. Caliceti,et al.  Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.

[112]  Y. Lin,et al.  Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. , 2001, Cancer biotherapy & radiopharmaceuticals.

[113]  C. Meares,et al.  Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  Y. Lin,et al.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.

[115]  W. Mcbride,et al.  Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. , 2000, Bioconjugate chemistry.

[116]  M. Adamo,et al.  Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach , 2000, European Journal of Nuclear Medicine.

[117]  E. Gautherot,et al.  Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[118]  P. Beaumier,et al.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  D. Fisher,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.

[121]  Y. Cao,et al.  Bispecific MAb Aided Liposomal Drug Delivery , 2000, Journal of drug targeting.

[122]  M. Goris,et al.  Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. , 1999, Cancer biotherapy & radiopharmaceuticals.

[123]  F. Kraeber-Bodéré,et al.  Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[124]  F. Kraeber-Bodéré,et al.  Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[125]  F. Kraeber-Bodéré,et al.  Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  A. Corti,et al.  Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. , 1999, Cancer research.

[127]  F. D. De Braud,et al.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.

[128]  M. Ferrari,et al.  Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.

[129]  E. Gautherot,et al.  Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[130]  F. D. De Braud,et al.  Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy , 1998, European Journal of Nuclear Medicine.

[131]  F. Kraeber-Bodéré,et al.  Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[132]  E. Gautherot,et al.  Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten , 1997, Cancer.

[133]  E. Gautherot,et al.  Pretargeted radioimmunotherapy using131I-labelled bivalent hapten-bearing peptides , 1997, Letters in Peptide Science.

[134]  G. Fulci,et al.  Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. , 1997, Cancer research.

[135]  F. Fazio,et al.  Biodistribution in tumour‐bearing mice of two 90Y‐labelled biotins using three‐step tumour targeting , 1997, Nuclear medicine communications.

[136]  M Bardiès,et al.  Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[137]  G. Veeneman,et al.  Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. , 1995, Bioconjugate chemistry.

[138]  D. Kukis,et al.  Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. , 1994, Cancer research.

[139]  M. Masserini,et al.  Characterisation of biotinylated liposomes for in vivo targeting applications , 1993, FEBS letters.

[140]  J. Slater,et al.  Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. , 1991, Cancer research.

[141]  E. Gautherot,et al.  In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[142]  R. W. Baldwin,et al.  Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. , 1988, Nuclear medicine communications.

[143]  D. Goodwin,et al.  Monoclonal antibody hapten radiopharmaceutical delivery , 1986, Nuclear medicine communications.

[144]  C. Meares,et al.  Antibodies against metal chelates , 1985, Nature.

[145]  M. Ginanneschi,et al.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®) , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[146]  Damon L. Meyer,et al.  Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. , 2005, Bioconjugate chemistry.

[147]  M. Bally,et al.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[148]  E. Gautherot,et al.  Pretargeted radioimmunotherapy using 131I-labelled bivalent hapten-bearing peptides , 2004, Letters in Peptide Science.

[149]  E. Gautherot,et al.  Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[150]  P. Beaumier,et al.  Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[151]  Domingo Rj,et al.  Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. , 2000 .

[152]  F. Kraeber-Bodéré,et al.  Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[153]  C. J. Boer,et al.  Bcl-1/cyclin D1 in malignant lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.